Latest research from the Griffith Health Institute has shown promising results for those suffering from non-Hodgkin Lymphoma.
Lymphoma is a common blood cancer, which develops in the lymphatic system affecting the white blood cells. Over the last 20 years, the number of cases in Australia have doubled.
In a recent study led by Professor Lyn Griffiths, the research team has identified a new tumour suppressor gene which affects susceptibility to two main types of non-Hodgkin Lymphoma (NHL).
“As part of a whole genome approach to identify the genes involved in NHL, we have identified a gene that plays a significant role in developing the two main types of NHL – Follicular Lymphoma and Diffuse Large B-cell Lymphoma,” says Professor Griffiths.
“38% of the NHL cases that we investigated had a mutation in this newly identified gene. We believe that the mutation in this gene makes them predisposed to the development and progression of these types of NHL.”
Supported by Cancer Council QLD and Griffith
Supported by funding from the Cancer Council of Queensland, and a part of the Griffith University Lymphoma Project (GULP), these results may have important implications for how we diagnose and treat this disorder in the future, says Professor Griffiths.
“Understanding the genetic mechanisms behind this disease may allow for the development of better diagnostic tools and improved therapies, ultimately improving the survival rates for patients.”
“Lymphoma is the most common blood cancer, being more common than both leukaemia and multiple myeloma. It causes 11 per cent of childhood cancers and is the most common cause of blood cancer death, with rates of lymphomas continuing to increase at 4 per cent per year,” says Professor Griffiths.
This trial is recruiting participants nationwide. To find out more please call 07 5552 9201 (leave name and phone number and you will be contacted by clinic staff) or email [email protected]